Basic Information
| RNALocate ID: | RLID:11000658 |
| RNA Symbol: | hsa-miR-15a-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-15a-5p |
| RNA ID: | miRBase:MIMAT0000068 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22211110 |
| Tissue/Cell Line: | Breast milk |
| Method: | Next-generation RNA sequencing |
|
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001249 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001250 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001251 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001252 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001253 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001254 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11000655 | Exosome | Serum | 18589210 |
| RLID:11000656 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000657 | Exosome | Renal cancer cells | 21670082 |
| RLID:11000659 | Exosome | Brain tissue | 23382797 |
| RLID:11000660 | Exosome | Plasma | 23663360 |
| RLID:11000661 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000662 | Exosome | Plasma | 24130905 |
| RLID:11000663 | Exosome | Serum | 25349172 |
| RLID:11000664 | Microvesicle | Plasma | 23077538 |
| RLID:11000665 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11000666 | Microvesicle | Hepatoma cells | 23771658 |
| RLID:11005565 | Exosome | Peripheral blood | 32785072 |
| RLID-D:11000007 | Exosome | Blood|B lymphoblastoid cells|Endothelial cells|Lymphoma tissue|Mast cells | |
| RLID-D:11000267 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-15a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-18022 |
| MNDR | hsa-miR-15a-5p | Polycystic liver disease | MNDR-E-MI-18023 |
| MNDR | hsa-miR-15a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-18024 |
| MNDR | hsa-miR-15a-5p | Peripheral arterial disease | MNDR-E-MI-18025 |
| MNDR | hsa-miR-15a-5p | Oral squamous cell carcinoma | MNDR-E-MI-18026 |
| MNDR | hsa-miR-15a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-18027 |
| MNDR | hsa-miR-15a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18028 |
| MNDR | hsa-miR-15a-5p | Lymphoma | MNDR-E-MI-18029 |
| MNDR | hsa-miR-15a-5p | Lymphoma non-hodgkin | MNDR-E-MI-18030 |
| MNDR | hsa-miR-15a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-18031 |
| MNDR | hsa-miR-15a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18032 |
| MNDR | hsa-miR-15a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-18033 |
| MNDR | hsa-miR-15a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18034 |
| MNDR | hsa-miR-15a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-18035 |
| MNDR | hsa-miR-15a-5p | Triple negative breast cancer | MNDR-E-MI-18036 |
| MNDR | hsa-miR-15a-5p | Acute promyelocytic leukemia | MNDR-E-MI-18037 |
| MNDR | hsa-miR-15a-5p | Breast cancer luminal | MNDR-E-MI-18038 |
| MNDR | hsa-miR-15a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-18039 |
| MNDR | hsa-miR-15a-5p | Prostate cancer | MNDR-E-MI-18040 |
| MNDR | hsa-miR-15a-5p | B-cell chronic lymphocytic leukemia | MNDR-E-MI-18041 |
| MNDR | hsa-miR-15a-5p | Gastric cancer | MNDR-E-MI-18042 |
| MNDR | hsa-miR-15a-5p | Gastric lymphoma | MNDR-E-MI-18043 |
| MNDR | hsa-miR-15a-5p | Alzheimer disease | MNDR-E-MI-18044 |
| MNDR | hsa-miR-15a-5p | Intracranial aneurysm | MNDR-E-MI-18045 |
| MNDR | hsa-miR-15a-5p | Esophageal carcinoma | MNDR-E-MI-18046 |
| MNDR | hsa-miR-15a-5p | Dysautonomia familial | MNDR-E-MI-18047 |
| MNDR | hsa-miR-15a-5p | Seizures | MNDR-E-MI-18048 |
| MNDR | hsa-miR-15a-5p | Huntington disease | MNDR-E-MI-18049 |
| MNDR | hsa-miR-15a-5p | Chorea | MNDR-E-MI-18050 |
| MNDR | hsa-miR-15a-5p | Cardiovascular disease | MNDR-E-MI-18051 |
| MNDR | hsa-miR-15a-5p | Moyamoya disease | MNDR-E-MI-18052 |
| MNDR | hsa-miR-15a-5p | Lung cancer | MNDR-E-MI-18053 |
| MNDR | hsa-miR-15a-5p | Endometrial cancer | MNDR-E-MI-18054 |
| MNDR | hsa-miR-15a-5p | Fragile x syndrome | MNDR-E-MI-18055 |
| MNDR | hsa-miR-15a-5p | Parkinson disease | MNDR-E-MI-18056 |
| MNDR | hsa-miR-15a-5p | Basal-like breast cancer | MNDR-E-MI-18057 |
| MNDR | hsa-miR-15a-5p | Pituitary neoplasms | MNDR-E-MI-18058 |
| MNDR | hsa-miR-15a-5p | Pancreatic cancer | MNDR-E-MI-18059 |
| MNDR | hsa-miR-15a-5p | Malignant melanoma | MNDR-E-MI-18060 |
| MNDR | hsa-miR-15a-5p | Gaucher disease | MNDR-E-MI-18061 |
| MNDR | hsa-miR-15a-5p | Rectum adenocarcinoma | MNDR-E-MI-18062 |
| MNDR | hsa-miR-15a-5p | Nephroblastoma | MNDR-E-MI-18063 |
| MNDR | hsa-miR-15a-5p | Colon cancer | MNDR-E-MI-18064 |
| MNDR | hsa-miR-15a-5p | Colon adenocarcinoma | MNDR-E-MI-18065 |
| MNDR | hsa-miR-15a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18066 |
| MNDR | hsa-miR-15a-5p | Familial ovarian cancer | MNDR-E-MI-18067 |
| MNDR | hsa-miR-15a-5p | Prostate adenocarcinoma | MNDR-E-MI-18068 |
| MNDR | hsa-miR-15a-5p | Kidney cancer | MNDR-E-MI-18069 |
| MNDR | hsa-miR-15a-5p | Carcinoma ductal breast | MNDR-E-MI-18070 |
| MNDR | hsa-miR-15a-5p | Glioblastoma | MNDR-E-MI-18071 |
| MNDR | hsa-miR-15a-5p | Astrocytoma | MNDR-E-MI-18072 |
| MNDR | hsa-miR-15a-5p | Glioma | MNDR-E-MI-18073 |
| MNDR | hsa-miR-15a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-18074 |
| MNDR | hsa-miR-15a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-18075 |
| MNDR | hsa-miR-15a-5p | Osteosarcoma | MNDR-E-MI-18076 |
| MNDR | hsa-miR-15a-5p | Liposarcoma | MNDR-E-MI-18077 |
| MNDR | hsa-miR-15a-5p | Infarction middle cerebral artery | MNDR-E-MI-18078 |
| MNDR | hsa-miR-15a-5p | Meningioma | MNDR-E-MI-18079 |
| MNDR | hsa-miR-15a-5p | Liver cancer | MNDR-E-MI-18080 |
| MNDR | hsa-miR-15a-5p | Gastric adenocarcinoma | MNDR-E-MI-18081 |
| MNDR | hsa-miR-15a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-18082 |
| MNDR | hsa-miR-15a-5p | Pituitary adenoma | MNDR-E-MI-18083 |
| MNDR | hsa-miR-15a-5p | Lung squamous cell carcinoma | MNDR-E-MI-18084 |
| MNDR | hsa-miR-15a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-18085 |
| MNDR | hsa-miR-15a-5p | Lung adenocarcinoma | MNDR-E-MI-18086 |
| MNDR | hsa-miR-15a-5p | Thyroid carcinoma | MNDR-E-MI-18087 |
| MNDR | hsa-miR-15a-5p | Papillary thyroid carcinoma | MNDR-E-MI-18088 |
| MNDR | hsa-miR-15a-5p | Ovarian carcinoma | MNDR-E-MI-18089 |
| MNDR | hsa-miR-15a-5p | Bladder urothelial carcinoma | MNDR-E-MI-18090 |
| MNDR | hsa-miR-15a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-18091 |
| MNDR | hsa-miR-15a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-18092 |
| MNDR | hsa-miR-15a-5p | Carcinoma renal cell | MNDR-E-MI-18093 |
| MNDR | hsa-miR-15a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18094 |
| MNDR | hsa-miR-15a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-18095 |
| MNDR | hsa-miR-15a-5p | Large cell carcinoma | MNDR-E-MI-18096 |
| MNDR | hsa-miR-15a-5p | Cholangiocarcinoma | MNDR-E-MI-18097 |
| MNDR | hsa-miR-15a-5p | Esophageal cancer | MNDR-E-MI-18098 |
| MNDR | hsa-miR-15a-5p | Oncocytoma | MNDR-E-MI-18099 |
| MNDR | hsa-miR-15a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-18100 |
| MNDR | hsa-miR-15a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-18101 |
| MNDR | hsa-miR-15a-5p | Acute t cell leukemia | MNDR-E-MI-18102 |
| MNDR | hsa-miR-15a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-18103 |
| MNDR | hsa-miR-15a-5p | Breast invasive carcinoma | MNDR-E-MI-18104 |
| MNDR | hsa-miR-15a-5p | Hepatocellular carcinoma | MNDR-E-MI-18105 |
| MNDR | hsa-miR-15a-5p | Familiar ovarian carcinoma | MNDR-E-MI-18106 |
| MNDR | hsa-miR-15a-5p | B-cell lymphoma | MNDR-E-MI-18107 |
| MNDR | hsa-miR-15a-5p | Rheumatoid arthritis | MNDR-E-MI-18108 |
| MNDR | hsa-miR-15a-5p | T-cell leukemia | MNDR-E-MI-18109 |
| MNDR | hsa-miR-15a-5p | Abdominal aortic aneurysm | MNDR-E-MI-18110 |
| MNDR | hsa-miR-15a-5p | Chronic myelogenous leukemia | MNDR-E-MI-18111 |
| MNDR | hsa-miR-15a-5p | Hodgkin lymphoma | MNDR-E-MI-18112 |
| MNDR | hsa-miR-15a-5p | Burkitt lymphoma | MNDR-E-MI-18113 |
| MNDR | hsa-miR-15a-5p | Myeloid leukemia | MNDR-E-MI-18114 |
| MNDR | hsa-miR-15a-5p | Neuromyelitis optica | MNDR-E-MI-18115 |
| MNDR | hsa-miR-15a-5p | Acute myelogenous leukemia | MNDR-E-MI-18116 |
| MNDR | hsa-miR-15a-5p | Colorectal cancer | MNDR-E-MI-18117 |
| MNDR | hsa-miR-15a-5p | Nasopharynx carcinoma | MNDR-E-MI-18118 |
| MNDR | hsa-miR-15a-5p | Tyrosinemias | MNDR-E-MI-18119 |
| MNDR | hsa-miR-15a-5p | Multiple myeloma | MNDR-E-MI-18120 |
| MNDR | hsa-miR-15a-5p | Acute lymphocytic leukemia | MNDR-E-MI-18121 |
| MNDR | hsa-miR-15a-5p | Ependymoma | MNDR-E-MI-18122 |
| MNDR | hsa-miR-15a-5p | Nasopharyngeal cancer | MNDR-E-MI-18123 |
| MNDR | hsa-miR-15a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-18124 |
| MNDR | hsa-miR-15a-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-18125 |
| MNDR | hsa-miR-15a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-18126 |
| MNDR | hsa-miR-15a-5p | Pituitary acth hypersecretion | MNDR-E-MI-18127 |
| MNDR | hsa-miR-15a-5p | Stroke lacunar | MNDR-E-MI-18128 |
| MNDR | hsa-miR-15a-5p | Breast cancer her3+ negative | MNDR-E-MI-18129 |
| MNDR | hsa-miR-15a-5p | Low grade dysplastic nodule | MNDR-E-MI-18130 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAMTS5 | Homo sapiens | RR00042323 |
TOP